BNTX Stock: Price, Forecast, Financials & AI Analysis

Loading...

High

111.260

Open

109.240

VWAP

109.59

Vol

1.19M

Mkt Cap

27.35B

Low

107.910

Amount

130.68M

EV/EBITDA(TTM)

--

Total Shares

250.93M

EV

11.48B

EV/OCF(TTM)

--

P/S(TTM)

7.06

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Show More

Events Timeline

(ET)

2026-01-16

16:30:00

S&P 500 Dips to 6940.01 Amid Mixed Earnings

2026-01-16

12:00:00

S&P 500 Nears 7,000 Amid Market Volatility

2026-01-12 (ET)

2026-01-12

07:50:00

BioNTech to Initiate 15 Phase 3 Trials in 2026

2026-01-05 (ET)

2026-01-05

14:40:00

CDC Revises Recommended Vaccines for Children to 11 Diseases

2025-12-09 (ET)

2025-12-09

14:10:00

FDA Expands Investigation into COVID-19 Vaccines

2025-12-09

07:30:00

BioNTech and Bristol Myers Squibb Announce Interim Data from Tumor Drug Trial

News

an image of stocktwits

01-16stocktwits

Goldman Sachs Upgrades BioNTech (BNTX) to Buy, Raises Price Target to $142

an image of Barron's

Stocks to Consider Buying in 2026: Insights from Our Roundtable Experts, Including DoorDash and LVMH

an image of CNBC

Deutsche Bank Upgrades Coupang to Buy, Strong Regulatory Resilience

an image of Benzinga

Topgolf Callaway and Others See Analyst Upgrades with Significant Price Target Increases

an image of Globenewswire

01-14Globenewswire

Oncolytics Biotech Appoints New Executives to Accelerate Cancer Treatment Progress

an image of seekingalpha

01-13seekingalpha

HHS Secretary Kennedy Appoints Two OB-GYN Experts to CDC's ACIP

15 Analyst Rating

Wall Street analysts forecast BNTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BNTX is 141.93 USD with a low forecast of 116.00 USD and a high forecast of 181.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

12 Buy

3 Hold

0 Sell

Strong Buy

Current: 0.000

Low

116.00

Averages

141.93

High

181.00

Current: 0.000

Low

116.00

Averages

141.93

High

181.00

Goldman Sachs

Neutral -> Buy

upgrade

$115 -> $142

Al Analysis

2026-01-16

New

Reason

Goldman Sachs

Price Target

$115 -> $142

Al Analysis

2026-01-16

New

upgrade

Neutral -> Buy

Reason

As previously reported, Goldman Sachs upgraded BioNTech to Buy from Neutral with a price target of $142, up from $115. With a broad, strategic suite of programs, the firm views BioNTech as "being at the nexus of significant developments occurring in the oncology field" and uniquely positioned to develop novel-novel combination approaches to transform cancer care, the analyst tells investors. Data unlocks in 2026 could position the company with "a leading foothold in an emerging wave of new product cycles," the analyst added.

Goldman Sachs

Neutral -> Buy

upgrade

$142

2026-01-16

New

Reason

Goldman Sachs

Price Target

$142

2026-01-16

New

upgrade

Neutral -> Buy

Reason

Goldman Sachs upgraded BioNTech to Buy from Neutral with a $142 price target.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BNTX

Unlock Now

Valuation Metrics

The current forward P/E ratio for Biontech SE (BNTX.O) is -17.54, compared to its 5-year average forward P/E of -5.30. For a more detailed relative valuation and DCF analysis to assess Biontech SE 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PE

-5.30

Current PE

-17.54

Overvalued PE

4.80

Undervalued PE

-15.41

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

an image of dotted line Image

N/A

5Y Average EV/EBITDA

2.59

Current EV/EBITDA

-6.46

Overvalued EV/EBITDA

12.55

Undervalued EV/EBITDA

-7.37

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

an image of dotted line Image

5Y Average PS

6.04

Current PS

9.14

Overvalued PS

8.87

Undervalued PS

3.21

Financials

Al Analysis

Annual

Quarterly

Trading Trends

People Also Watch

Frequently Asked Questions

What is Biontech SE (BNTX) stock price today?

The current price of BNTX is 109 USD — it has increased 2.76 % in the last trading day.

What is Biontech SE (BNTX)'s business?

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

What is the price predicton of BNTX Stock?

Wall Street analysts forecast BNTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BNTX is141.93 USD with a low forecast of 116.00 USD and a high forecast of 181.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Biontech SE (BNTX)'s revenue for the last quarter?

Biontech SE revenue for the last quarter amounts to 1.52B USD, increased 22.02 % YoY.

What is Biontech SE (BNTX)'s earnings per share (EPS) for the last quarter?

Biontech SE. EPS for the last quarter amounts to -0.12 USD, decreased -114.81 % YoY.

How many employees does Biontech SE (BNTX). have?

Biontech SE (BNTX) has 6772 emplpoyees as of January 20 2026.

What is Biontech SE (BNTX) market cap?

Today BNTX has the market capitalization of 27.35B USD.